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ABSTRACT
Background: The clinical efficacy of combination therapy comprising a long acting β2-agonist (LABA) and
corticosteroid is widely recognized for the treatment of adult asthma. Here we examine the effect of salmeterol
xinafoate (SX) and fluticasone propionate (FP) alone and in combination on the immunological activation of hu-
man cultured mast cells (HCMC) in vitro.
Methods: HCMC were passively sensitized with IgE antibody and then activated by challenging with anti-IgE
antibody. The effect of drugs on the activation of mast cells was examined by measuring the amount of re-
leased chemical mediators (histamine, leukotrienes (LT) and prostaglandin D2 (PGD2 )) and granulocyte
macrophage colony stimulating factor (GM-CSF).
Results: The release of each chemical mediator was inhibited by 10−9―10−8M SX but not by 10−10―10−7M FP.
The production of GM-CSF was inhibited by a concentration of 10−8M in both drugs and the inhibition was aug-
mented by combined treatment with 10−11M of each drug.
Conclusions: The immunological release of chemical mediators (histamine, LT, PGD2) from HCMC was in-
hibited by SX but not by FP. SX and FP inhibited the production of GM-CSF by HCMC and both drug showed
synergistic inhibition in the production of GM-CSF.
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INTRODUCTION
Over the last decade there has been a dramatic im-
provement in the treatment of allergy, largely due to
the early use of potent anti-allergic or anti-
inflammatory drugs . 1-3 For example , bronchial
asthma can be effectively managed using an inhaled
corticosteroid with or without β2-agonists. However
in patients with severe bronchial asthma, theophyl-
line and an anti-cholinergic bronchodilator are also
used.4-6 Whereas short acting β2-agonists are very ef-
fective in the relief of symptoms due to bronchodila-
tor effects , occasionally some patients experience
tremor and palpitations.7,8 These adverse effects can
usually be avoided by reducing the dose andor fre-
quency of the β2-agonist and by combination therapy
with other drugs , including anti-cholinergic bron-
chodilator or glucocorticoids.9,10
Recently , long acting β 2-agonists (LABAs) have
been introduced for the treatment of bronchial
asthma.11,12 LABA, salmeterol and formoterol have
prolonged smooth muscle effects and a high affinity
for the β2-receptor compared to salbutamol . 13 The
pharmacological activity of LABAs is not restricted to
airway smooth muscle because these agents also in-
hibit mast cell mediator release and pro-inflammatory
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Table 1 Efects of SX and Isoproterenol on IgE-mediated Histamine, LTs and PGD2 Release
PGD2 (pg/mL)     LTs (pg/mL)     Histamine (%)  Concentration (M)
＋＋＋322.12＋＋＋106.78＋＋＋5.02Spon
17719.4736311.4558.93Control
20348.6941797.6555.2810 －12
17692.8635360.2752.3310 －11
13072.12＊15915.31＊32.5210 －10
8100.66＊＊8818.88＊＊＊20.7610 －9 
＊7036.74＊＊6777.65＊＊＊18.7010 －8 
＋2346.27＋＋＋1056.62＋＋＋9.60ISO
Each figure represents the mean of three to five experiments. For clarity, standard eror is not shown, but it was less than 18.2% of the 
mean value at each point. HCMC were passively sensitized by incubation with 1 μg/ml human myeloma IgE overnight. HCMC were 
treated with each drug for 10 minutes and then stimulated with anti-IgE antibody for 30 minutes.
＊, ＊＊, ＊＊＊: p＜0.05, 0.01 and 0.001 (vs control; Dunnet’ smultiple range test)
＋, ＋＋＋: p＜0.05 and 0.001 (vs control; Student’ st-test)
cytokine production following segmental allergen
challenge of atopic asthma patients . 14 In addition ,
LABA was shown to produce a clinically relevant re-
duction in inhaled steroid dose, in addition to strong
bronchodilation. Furthermore, there is growing evi-
dence to suggest that LABA has complementary ac-
tions to glucocorticoids . For example , LABA in-
creases glucocorticoid induced-eosinophil apoptosis,
inhibition of cytokinechemokine release and respira-
tory mucosal cytoprotection.15-18
This study was conducted to investigate the com-
plementary action of LABAs and glucocorticoids on
the immunological activation of human cultured mast
cells (HCMC). We chose salmeterol xinafoate (SX)
as the LABA and fluticasone propionate (FP) as the
glucocorticoid. The activation of HCMC was exam-
ined by measuring the released chemical mediators
(histamine, leukotriene (LT) and prostaglandin D2
( PGD 2 ) ) and the production of granulocyte-
macrophage colony stimulating factor (GM-CSF) af-
ter stimulation with anti-IgE antibody.
METHODS
DRUGS
SX and FP were kindly donated by GlaxoSmithKline
K.K. (Tokyo, Japan). These drugs were dissolved in
dimethyl sulfoxide and stored. Isoproterenol was pur-
chased from Sigma-Aldrich Co. (St. Louis, MO, USA).
MAST CELL CULTURE
HCMC were obtained by culturing progenitor cells in
human umbilical cord blood donated from healthy
mothers after obtaining informed consent at Ogaki
Municipal Hospital, Gifu, according to the method de-
scribed by Saito et al.19,20 with some modifications.
Briefly, freshly obtained heparin-treated cord blood
was layered on a lymphocyte separating medium
(ICN Biomedicals, Inc., Aurora, OH, USA) and centri-
fuged. The mononuclear cell layer was collected and
CD34 positive cells were purified using a CD34 isola-
tion kit and Magnetic Cell Sorting System (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany). Puri-
fied CD 34 positive cells were cultured in an α-
minimum essential medium (Sigma-Aldrich) contain-
ing 15% fetal bovine serum (Thermo Trace Ltd., Mel-
bourne, Australia ) , 80 ngml human recombinant
stem cell factor (Kirin Brewery Co., Ltd., Maebashi,
Japan) and 50 ngml human recombinant interleukin-
6 (Kirin Brewery, Maebashi, Japan). Cells were har-
vested weekly and resuspended in a fresh medium.
The purity of mast cells was determined by toluidine
blue-staining. Beyond 12 weeks, almost 100% of the
cultured cells were mast cells.
CHEMICAL MEDIATOR RELEASE AND CY-
TOKINE PRODUCTION
HCMC were sensitized with 1 μgmL human
myeloma IgE (Chemicon Int . Inc. , Temecula , CA,
USA) at 37℃ overnight. In the experiment on IgE-
mediated chemical mediator ( histamine , LTs and
PGD2) release, cells were resuspended at a concen-
tration of 1×105 cellsml in Tyrode’s solution (126
mM NaCl, 4 mM KCl, 0.64 mM NaH2PO4, 1 mM
CaCl2, 0.6 mM MgCl2, 0.1% glucose, 0.03% bovine se-
rum albumin (BSA), 10 mM HEPES, pH 7.4). The
cell suspension was pretreated with each drug for 10
minutes and then challenged with 4 μgml anti-
human IgE antibody (DAKO, Glostrup, Denmark) for
30 minutes at 37℃ . To examine the effect of the
agents on cytokine (GM-CSF) production, cells were
resuspended at a concentration of 1×106 cellsml in
fresh culture medium, pretreated with each drug for
10 min and then challenged with 1.5 μgml anti-
human IgE for 6 hours at 37℃. After stimulation with
anti-IgE, reaction mixtures were centrifuged and the
supernatants were separated and stored until meas-
urement.
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Fig. 1 Efects of salmeterol, fluticasone and isoproterenol on IgE-mediated GM-CSF pro-
duction from HCMC. HCMC were passively sensitized with 1 μg/mL human myeloma IgE 
overnight. HCMC were treated with each drug for 10 minutes and then stimulated with anti-
IgE for 30 minutes or 6 hours. Each result represents the mean of the S.E.M. of three to 
four independent experiments. Cont: control, Iso: isoproterenol, Spon: spontaneous. ＊, 
＊＊, ＊＊＊: p＜ 0.05, 0.01, 0.001 (vs Cont; Dunnet’s multiple range test). ＋＋, ＋＋＋: p＜
0.001 (vs Cont; Student’s t-test).
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Table 2 Efects of FP and Isoproterenol on IgE-mediated Histamine, LTs and PGD2 Release
PGD2 (pg/mL)     LTs (pg/mL)     Histamine (%)  Concentration (M)
＋＋＋4.27＋＋＋1605.23＋＋＋2.55Spon
10339.7415599.2449.48Control
11538.1919058.5158.3410 －10
13199.2019129.2863.5010 －9
12993.8015098.6163.9910 －8
12923.9313228.6062.0310 －7
＋＋＋1132.64＋＋＋3271.16＋＋＋7.52ISO
Each figure represents the mean of three to five experiments. For clarity, standard eror is not shown, but it was less than 21.5% of the 
mean value at each point. HCMC were passively sensitized by incubation with 1 μg/ml human myeloma IgE overnight. HCMC were 
treated with each drug for 10 minutes and then stimulated with anti-IgE antibody for 30 minutes.
＋＋＋: p＜0.001 (vs control; Student’ st-test).
MEASUREMENT OF HISTAMINE , LTS , PGD 2
AND GM-CSF
Histamine content was quantified by the method of
post-column derivatization as previously reported. 21
Histamine release is expressed as the percentage of
total histamine content determined by cell lysis with
perchloric acid. For the analysis of LTs, we used a
commercial ELISA kit provided by BÜhlmann Labora-
tories AG (Allschwil, Switzerland). The ELISA kit was
based on the monoclonal antibody that recognizes
sulfidoleukotrienes (LTC4, LTD4 and LTE4). PGD2
was measured by PGD 2-MOX EIA kit ( Cayman
Chemical Co., Ann Arbor, MI, USA). This kit is based
on the conversion of PGD2 to a stable methoxime de-
rivative by treatment with methoxamine hydrochlo-
ride. GM-CSF content in the supernatants was meas-
ured with an ELISA kit (R&D Systems, Minneapolis,
MN, USA), according to the manufacture’s protocol.
STATISTICS
All data are represented as the mean ± S.E.M of three
or four independent experiments and analyzed using
Dunnett’s multiple range test and Student’s t -test.
RESULTS
EFFECTS OF SX AND FP ON THE RELEASE OF
HISTAMINE, LTS AND PGD2 FROM HCMC
Firstly, we examined the effect of SX and FP on the
release of chemical mediators from HCMC . After
stimulation with anti-human IgE antibody, the level of
histamine, LTs and PGD2 in the supernatant was sig-
nificantly elevated. As shown in Table 1, SX (10−11 ―
10−8 M) showed a tendency to inhibit or inhibited the
release of histamine, LT and PGD2 in a concentration-
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Fig. 2 Combined efects of salmeterol and fluticasone on IgE-mediated GM-CSF pro-
duction from HCMC. HCMC were passively sensitized with 1 μg/mL human myeloma 
IgE overnight. HCMC were treated with each drug for 10 minutes and then stimulated 
with anti-IgE for 6 hours. Each result represents the mean with the S.E.M. of three or 
four independent experiments. (a) Inhibitory efect of salmeterol alone (□) or salme-
terol with 1×10－11 M fluticasone (■). (b) Inhibitory efect of fluticasone alone (□) or 
fluticasone with 1×10－11 M salmeterol (■). (c) Comparison of the inhibitory efects of 
fluticasone and salmeterol alone or in combination. SM: 1×10－11 M salmeterol, FP: 
1×10－11 M fluticasone. ＋＋, ＋＋＋: p＜0.01 and 0.001 (vs alone; Student’s t-test).
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dependent manner. SX showed no inhibitory effect at
1×10−11 M, but significantly inhibited the release of
chemical mediators at a concentration of 1×10−8M.
Pretreatment with FP did not affect the release of the
chemical mediators (Table 2). Isoproterenol at a con-
centration of 10−8M, which was used as a positive
control, clearly inhibited the release of histamine, LT
and PGD2.
EFFECT OF SX AND FP ON THE PRODUCTION
OF GM-CSF BY HCMC
Treatment of HCMC with either SX or FP inhibited
the production of GM-CSF in a concentration-
dependent manner ( i.e. no effect on GM-CSF produc-
tion at 1×10−12 M, but complete inhibition at 1×10−8
M). Isoproterenol at a concentration of 1×10−7 M
completely inhibited the production of GM-CSF(Fig.
1).
We also examined the effect of combined treat-
ment of HCMC with SX and FP. The inhibition of
GM-CSF production by SX at concentrations between
1×10−12 and 1×10−10 M was clearly augmented by
the addition of 1×10−11 M FP (Fig. 2(a)). Further-
more, the inhibition by FP at concentrations between
1×10−13 M and 1×10−11 M was clearly potentiated by
the addition of 1×10−11 M SX, although no synergis-
tic effect was observed at a concentration of 1×10−10
M FP (Fig. 2(b)). The inhibition of GM-CSF produc-
tion by SX (1×10−11 M) and FP (1×10−11 M) alone
and in combination is depicted in Figure 2(c) . Al-
though the inhibition of GM-CSF production by SX
and FP was 14 and 41%, respectively, it reached 91%
when the drugs were used in combination. When the
combined effect on the release of histamine was ex-
amined under the same conditions, no synergistic ef-
fect was observed.
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DISCUSSION
In this study, we investigated the effects of SX and FP
alone or in combination on IgE-mediated mast cell ac-
tivation, including chemical mediator release and cy-
tokine production by human mast cells derived from
cord blood progenitor cells.
We initially examined the effect of these drugs on
chemical mediator release from mast cells. Our re-
sults indicate that SX inhibits the release of hista-
mine, LTs and PGD2 in a concentration-dependent
manner. The same affect is also observed for isopro-
terenol. Our previous data indicated that β2 agonists
are strong inhibitors of mediator release from mast
cells when compared to the effect of mast cell stabiliz-
ers, such as disodium cromoglycate and azelastine.22
Furthermore, Chong et al. also demonstrated that SX
inhibits chemical mediator release from human lung
mast cells.23 They reported that β2 agonists elevate
intracellular cAMP levels through β2 adrenoceptors,
resulting in the activation of a downstream effector,
protein kinase A, that plays a key role in the inhibi-
tory effects of the secretion of chemical mediators in
addition to the relaxation of smooth muscle cells. Our
previous studies using rat mesenteric mast cells also
indicate the same mechanism.24 Further experiments
designed to measure the level of cAMP in mast cells
will be necessary to explain an anti-inflammatory ac-
tivity of SX in the acute phase reaction.
In contrast to β2 agonists, FP did not show any in-
hibitory effect on mediator release from mast cells.
Our preliminary experiments using HCMC and hu-
man lung tissues also indicated that prednisolone and
dexamethasone failed to inhibit allergic chemical me-
diator release (data not shown) . Similar data has
been reported by other investigators.25-27 These ex-
periments suggest that corticosteroids do not directly
affect chemical mediator release from human mast
cells. However some investigators reported that there
is an inhibitory action of glucocorticoids on the matu-
ration of human mast cells , which results in a de-
crease in tissue mast cells by reducing the production
of the c-kit ligand, a stem cell factor.28,29 These data
suggest that the main mechanism of glucocorticoid
induced inhibition of allergic mediator release may
be related to a mechanism other than mast cell activa-
tion.
In contrast to allergic chemical mediators, SX and
FP clearly inhibit the production of GM-CSF by
HCMC even at low concentrations. Whereas numer-
ous studies have demonstrated the inhibitory action
of glucocorticoids on the production of cytokines,30-34
only a few studies have been carried out to examine
the effect of β2-agonists on the production of cytoki-
nes by HCMC.35 The present study has clearly dem-
onstrated the efficacy of SX on the production of GM-
CSF by HCMC activated through immunological
stimuli. Combination therapy using SX and FP has re-
cently been recognized as a potent treatment for
bronchial asthma. Therefore we also examined the ef-
fect of SX and FP in combination on the production of
GM-CSF by HCMC. The present results clearly dem-
onstrate that the inhibition of GM-CSF production
from human mast cells is synergistically potentiated
by simultaneous treatment with low concentrations of
SX and FP. The anti-inflammatory activity of β2 ago-
nists detected in basic studies has not been clinically
evaluated. Thus it is not known whether β2 agonist
enhance the anti-inflammatory activity of corticoster-
oids in clinical practice. Indeed, the potentiation of
the anti-inflammatory activity of corticosteroids by β2
agonists may have important implications concerning
the clinical efficacy of the combined use of these two
drugs.
Regarding the effect of other cytokine production,
we did not try to measure any other cytokine without
GM-CSF in this experiment. However some investi-
gators reported a synergistic action of SX and FP on
the inhibition of IL-5 production and IL-10 secretion
by CD4＋T cells.36-38 Further experiments designed
to measure IL-5 or other cytokine production by
HCMC is necessary in near future.
Similar synergistic effects were reported for SX and
FP on the in vitro production of TNF- α-induced IL-8
and eotaxin by human airway smooth muscle cells
and human lung fibroblasts . 39-41 Moreover , other
combinations of LABA and ICS, such as formoterol
and budesonide, also depress cytokine production in
human bronchial epithelial cells.42 These reports to-
gether with the results presented in this paper sup-
port the clinical efficacy of combination therapy for
LABA and ICS in the treatment of bronchial asthma.
The addition of salmeterol to ICS gives improved
lung function and symptom control in asthmatic pa-
tients and is more effective than doubling the dose of
ICS.43,44 We predict that combination therapy with SX
and FP will soon become the major treatment for
asthma in Japan. The underlying mechanism for the
combined use of the two drugs was not examined in
the present study. Some studies have indicated that
corticosteroids increase the expression of β2 adreno-
ceptors and that β2 agonists activate the glucocorti-
coid receptor . 45,46 These mechanisms may explain
the efficacy of combination therapy. We plan to inves-
tigate the molecular mechanism of combined therapy
including c-AMP levels , mRNA expression of func-
tional molecules and alternation of nucleic factors in
near future. This is the first report to demonstrate the
combination effect of SX and FP on HCMC. Our re-
sults support the clinical efficacy of combination ther-
apy comprising LABA and ICS for the treatment of
asthma.
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